经肝动脉化疗栓塞术联合索拉非尼治疗晚期肝细胞癌完全缓解1例报告

马菁璠; 陈刚; 刘洪

doi:10.3969/j.issn.1001-5256.2016.01.030

经肝动脉化疗栓塞术联合索拉非尼治疗晚期肝细胞癌完全缓解1例报告

DOI: 10.3969/j.issn.1001-5256.2016.01.030

昆明医科大学附属甘美医院肝胆外科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2041
- HTML全文浏览量: 22
- PDF下载量: 391
- 被引次数: 0
出版历程
- 出版日期: 2016-01-20

TACE combined with sorafenib in treatment of advanced primary hepatocellular carcinoma: a report of one case achieving complete response

Department of Hepatobiliary Surgery,Ganmei Hospital Affiliated to Kunming Medical University

摘要

摘要: <正>据报道[1]每年约有750 000例肝癌新增病例,且逐年递增,其中80%85%的肝癌患者被确诊时已丧失手术机会。不能手术的患者,可采用多种局部治疗方法,其中经肝动脉化疗栓塞术（transcatheter arterial chemoembolization,TACE）为首选治疗方法[2-3],可取得较好的近期疗效。但它只能使肿瘤大部分坏死,早期的缺氧环境,会造成血管内皮生长因子生成增
- 癌,肝细胞 /
- 化学栓塞,治疗性 /
- 索拉非尼 /
- 病例报告
- carcinoma,hepatocellular /
- chemoembolization,therapeutic /
- sorafenib /
- case reports

HTML全文

参考文献(23)

[1]KOUDAH S,EL MOUHADI S,ARRIVL.Fibrolamellar hepatocellular carcinoma[J].Clin Res Hepatol Gastroenterol,2012,36(1):5-6.

[2]YANG M,YUAN JQ,BAI M,et al.Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma:a systematic review and meta-analysis[J].Mol Biol Rep,2014,41(10):6575-6582.

[3]ZHANG L,HU P,CHEN X,et al.Transarterial chemoembolization(TACE)plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma:a meta-analysis[J].PLoS One,2014,9(6):e100305.

[4]NITTA H,BEPPU T,IMAI K,et al.Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion[J].World J Surg,2013,37(5):1034-1042.

[5]KEE KM,HUNG CH,WANG JH,et al.Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib[J].Onco Targets Ther,2014,7:829-834.

[6]IMEDIO ER,BEVERIDGE RD,URTASUN JA,et al.Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma:a single center experience[J].Med Oncol,2014,31(5):948.

[7]GADALETA-CALDAROLA G,INFUSINO S,GALISE I,et al.Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma:a phaseⅡstudy[J].Oncol Lett,2014,8(4):1783-1787.

[8]RICKE J,BULLA K,KOLLIGS F,et al.Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma:analysis of the European multicentre trial SORAMIC[J].Liver Int,2015,35(2):620-626.

[9]LLOVET JM,RICCI S,MAZZAFERRO V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.

[10]CHENG AL,KANG YK,CHEN Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phaseⅢrandomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2009,10(1):25-34.

[11]RONOT M,BOUATTOUR M,WASSERMANn J,et al.Alternative response criteria(Choi,European association for the study of the liver,and modified response evaluation criteria in solid tumors[RECIST])versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib[J].Oncologist,2014,19(4):394-402.

[12]YADA M,MASUMOTO A,MOTOMURA K,et al.Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma[J].World J Gastroenterol,2014,20(35):12581-12587.

[13]ZHENG YB,ZHAN MX,ZHAO W,et al.The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib[J].Med Oncol,2014,31(10):209.

[14]SO BJ,BEKAII-SAAB T,BLOOMSTON MA,et al.Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis:a case report[J].J Hematol Oncol,2008,1:18.

[15]LULLA PD,BRAMMER JE,BANDEALI S,et al.Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib[J].J Gastrointest Cancer,2013,44(1):98-101.

[16]WANG SX,BYRNES A,VERMA S,et al.Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib:a case report[J].Target Oncol,2010,5(1):59-63.

[17]SHOMURA M,KAGAWA T,SHIRAISHI K,et al.Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma[J].World J Hepatol,2014,6(9):670-676.

[18]AKUTSU N,SASAKI S,TAKAGI H,et al.Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy[J].Int J Clin Oncol,2015,20(1):105-110.

[19]TANOGLU A,KARAGOZ E.Predictive role of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma receiving sorafenib[J].Asian Pac J Cancer Prev,2014,15(2):1063.

[20]SHAO YY,LIN ZZ,HSU C,et al.Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma[J].Cancer,2010,116(19):4590-4596.

[21]LEE S,KIM BK,KIM SU,et al.Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy:a Korean multicenter study[J].J Gastroenterol Hepatol,2014,29(7):1463-1469.

[22]TSUCHIYA K,ASAHINA Y,MATSUDA S,et al.Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma[J].Cancer,2014,120(2):229-237.

[23]NAGAI H,KANEKAWA T,KOBAYASHI K,et al.Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib[J].Cancer Chemother Pharmacol,2014,73(2):223-229.

施引文献

资源附件(0)

访问统计